Kristoffer Lindstrom: Physitrack (PTRK) Deep Dive & More

Episode Summary

Executive Summary: The episode features Brandon interviewing Christopher Lindstrom of Lind Research about his career path, investing philosophy, and detailed bullish thesis on Swedish microcap PhysiTrack (PTRK). Lindstrom argues the market misunderstands the company due to weak reporting, founder selling, and a troubled wellness segment, while underappreciating the sticky, high-margin Life Care SaaS business and operational improvements underway.

Main Topics: Christopher Lindstrom’s investing background (Priority: 5/5): Lindstrom describes an early start in investing, from bank work to equity research at Red Eye and later operating roles, which shaped his style of small-cap, hands-on investing. Launching Lind Research and active value philosophy (Priority: 5/5): He explains why he started publishing research independently, focusing on neglected Nordic micro/small caps where research can influence outcomes and help close valuation gaps. PhysiTrack thesis: undervaluation and misperception (Priority: 5/5): The core pitch is that PTRK is deeply neglected and misunderstood, with the market overly focused on weak segments and missing the quality of the Life Care SaaS business. Segment analysis: Life Care vs Wellness (Priority: 5/5): Lindstrom separates PhysiTrack into a strong, recurring-revenue Life Care software business and a weaker Wellness segment that had M&A missteps but is now being restructured. Position sizing, liquidity, and conviction (Priority: 4/5): He discusses building a large position gradually due to low liquidity, ultimately making PhysiTrack around 50% of his portfolio because of the asymmetric setup. Comparables, valuation, and upside framing (Priority: 4/5): He uses Nordic SaaS peers and forward multiples to argue the stock is far below fair value, with Life Care alone potentially worth multiples of the current enterprise value. Other ideas: Better Collective, Embracer, Sleep Cycle (Priority: 3/5): He briefly highlights other Nordic opportunities and special situations he is tracking, including an industry-informed negative view on Better Collective and bullish cases on Embracer spin-offs and Sleep Cycle.

Key Arguments: Lindstrom’s edge comes from deep small-cap coverage, operating experience, and the ability to engage with management rather than just passively model companies. PhysiTrack is mispriced because investors focus on the underperforming Wellness segment and ignore the high-quality, sticky Life Care SaaS business. The Life Care business has strong recurring revenue, pricing power, and margins, making it comparable to higher-multiple Nordic SaaS peers. The company’s weak reporting and a founder’s market selling created an overhang that obscured intrinsic value. Management has begun implementing the suggested fixes: cost cuts, restructuring, better reporting, and cash-flow focus, which could unlock rerating. Low liquidity makes the stock difficult to accumulate, but also supports the possibility of large future returns if the thesis works. He prefers companies where either durable competitive advantages or mean reversion can be bought at a discount to private-market value. He looks for cases where public-market neglect creates information asymmetry and where operational improvements can directly affect valuation.

Data Points: Age investing interest began: 15-16 - Lindstrom says he became interested in investing as a teenager. Current age: 36 - He notes his age while describing his investing career arc. Red Eye coverage: 8-10 companies - As an equity analyst, he covered a focused portfolio of small-cap companies. PhysiTrack valuation at entry: EV/sales 1.5x - He says the company was extremely cheap when he began buying. Life Care growth: 10-15% - He describes the core Life Care business as growing at this pace. Life Care EBITDA margin: 40% - He cites very strong profitability for the SaaS segment. Life Care EBIT margin: 20% - He says the business has strong operating leverage and margins. Annual price increases: 5-10% - He says PhysiTrack has been able to raise prices with little customer impact. Life Care valuation relative to company: 3x the whole company value - He argues the Life Care segment alone was worth roughly three times the market value of the whole company at the time. Portfolio weight in PhysiTrack: 50% - He says the position became his largest conviction idea. Initial buy price: ~9 SEK - He began building the position around this level. Price range during accumulation: up to ~12 SEK - He continued adding as conviction increased. Cash: ~$600,000 - Brandon raises balance sheet concerns using this figure. Debt: ~$5 million - He notes the company’s debt load during the balance sheet discussion. Maintenance capex: ~$600,000 - Compared with cash, used to illustrate the balance sheet question. Current company market cap: ~$29 million - Brandons looks up the microcap size on Koyfin. Historical peak market cap: ~$80 million USD (2021) - The stock had previously been much larger before declining. Comparable SaaS EV/sales median: 6.4x - He discusses Nordic SaaS comps used in valuation work. Fortnox EV/sales: 19.2x - Used as an example of a premium Nordic SaaS multiple. Life Care valuation estimate: ~$42 million revenue-based midpoint - Brandon summarizes a segment valuation exercise for the Life Care business. Adjusted EBIT valuation estimate: ~$54 million midpoint - Brandon cites the EBIT-based segment value estimate. User scale at Sleep Cycle: 2.8-3.0 million active monthly users - Lindstrom describes the size of the app user base. Sleep Cycle paying users: ~900,000 - He distinguishes paid subscribers from free users. Sleep Cycle enterprise value: ~$45 million - He characterizes the valuation as cheap relative to cash generation. Sleep Cycle cash: ~$15 million - He notes the business has a substantial cash balance. Sleep Cycle market cap: ~$61 million - He references the equity value while discussing dividends and cash. Sleep Cycle dividend history: $14 million in 2023; $4 million in 2024 - He cites prior distributions to show capital returns. Better Collective report timing: “today” - He mentions a fresh report as he discusses the company negatively. Embracer spin-off: Asmodee spun off; Coffee Stain upcoming - He frames these as value-unlocking corporate actions. Founder ownership in Sleep Cycle: ~45% - He says this provides an aligned insider setup. PhysiTrack founder ownership: ~25% - He notes the CEO/founder’s significant stake.

Pivotal Quotes: "If I hear an idea once, I kind of forget about it. If I hear an idea twice, I should put it on my watch list. And then, if I hear it from a third person that's different, then it's like, okay, I must do the immediate buy." — Christopher Lindstrom: Explains his mental framework for idea generation and conviction building. "I almost call it active value that you engage also with the company." — Christopher Lindstrom: Describes his style of small-cap investing as research plus direct engagement to close valuation gaps. "The high-level pitch is basically that it's extremely neglected and misunderstood." — Christopher Lindstrom: Summarizes the thesis for PhysiTrack.

Implications: The episode highlights how Nordic microcaps can be mispriced due to poor disclosure and low attention, creating room for active investors to influence outcomes. It also shows that operational fixes and better reporting can materially change market perception and rerate a stock.